City Therapeutics Inc.
CTYNews
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that data from its CITY-FXI and CITY-TFR2 programs will be presented at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12–15, 2026, in New Orleans, Louisiana.
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that management will participate in the following investor conferences in November.
As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Addition
Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research is expected to for one company in the week ahead, and four lock-up periods will be expiring.
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized initial public offering of 11,111,111 shares of its common stock at a public offering price of $18.00 per share.
City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market uncertainty.
City Therapeutics is advancing next-generation RNAi therapeutics, with its lead program CITY-FXI targeting thrombosis and showing promising early Phase 1 trial results. CTY boasts significant big pharma collaborations, a strong investor syndicate, and experienced leadership, positioning it as a high-quality biopharma IPO candidate. IPO proceeds will fund CITY-FXI clinical trials, advance additional pipeline assets, and support platform development, with a typical 18-month cash runway targeted.